183365-31-3

Usage

Uses

Used in Scientific Research:
3-(PYRROLIDIN-1-YLMETHYL)ANILINE is used as a research compound for the development and synthesis of various industrial-grade materials. Its unique chemical structure allows for exploration in different fields of study, contributing to the advancement of scientific knowledge and the creation of new materials.
Used in Industrial Material Synthesis:
3-(PYRROLIDIN-1-YLMYL)ANILINE is used as a key component in the synthesis of industrial materials. Its presence in the chemical reactions can lead to the production of materials with specific properties, making it a valuable resource in the manufacturing process.
Used in Pharmaceutical Development:
3-(PYRROLIDIN-1-YLMETHYL)ANILINE is used as a starting material or intermediate in the synthesis of pharmaceutical compounds. Its unique structure may contribute to the development of new drugs with potential therapeutic applications.
Used in Chemical Research:
3-(PYRROLIDIN-1-YLMETHYL)ANILINE is used as a reagent in chemical research, allowing scientists to study its properties and interactions with other compounds. This can lead to a better understanding of its potential applications and the discovery of new chemical reactions.

InChI:InChI=1/C11H16N2/c12-11-5-3-4-10(8-11)9-13-6-1-2-7-13/h3-5,8H,1-2,6-7,9,12H2

Upstream product

• 99-61-6 3-nitro-benzaldehyde 
• 160647-74-5 (3-aminophenyl)-(pyrrolidin-1-yl)methanone 
• 415931-07-6 1‐[(3‐nitrophenyl)methyl]pyrrolidine 

Downstream Products

• 945104-38-1 3-(4-tert-butylphenyl)-5,5-dimethyl-1-[(2-{[3-(pyrrolidin-1-ylmethyl)phenyl]amino}pyridin-4-yl)-methyl]imidazolidine-2,4-dione 
• 1071216-89-1 7-chloro-N-[3-(pyrrolidin-1-ylmethyl)phenyl]quinolin-4-amine 
• 1443438-09-2 C₂₆H₂₇F₆N₃O₂ 
• 1022980-80-8 C₂₀H₁₉N₃O 
• 1160623-14-2 N-(3-(2-amino-5-(2-((3-(1-pyrrolidinylmethyl)phenyl)amino)-4-pyrimidinyl)-1,3-thiazol-4-yl)phenyl)-2,6-difluorobenzamide 
• 1160623-76-6 2,6-difluoro-N-(3-(2-(4-methyl-1-piperazinyl)-5-(2-((3-(1-pyrrolidinylmethyl)phenyl)amino)-4-pyrimidinyl)-1,3-thiazol-4-yl)phenyl)benzamide 
• 1160625-17-1 2,6-difluoro-N-(3-(2-methyl-5-(2-((3-(1-pyrrolidinylmethyl)phenyl)amino)-4-pyrimidinyl)-1,3-thiazol-4-yl)phenyl)benzamide 
• 941319-27-3 N-{2-Methyl-5-[3-(2-{[3-(1-pyrrolidinylmethyl)phenyl]amino}-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl}-2-(2-thienyl)acetamide 
• 1142945-99-0 [4-(4-methyl-thiophen-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-(3-pyrrolidin-1-ylmethyl-phenyl)-amine 
• 217942-75-1 3-(2-chloro-phenyl)-2-[(3-pyrrolidin-1-ylmethyl-phenylamino)-methyl]-3H-thieno[3,2-d]pyrimidin-4-one hydrochloride 
• 875798-61-1 C₂₅H₂₅N₅O₃S 
• 188263-54-9 6-tert-Butyl-8-isocyanato-4-oxo-4H-chromene-2-carboxylic acid (3-pyrrolidin-1-ylmethyl-phenyl)-amide 

Relevant academic research and scientific papers

DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS

The present invention provides novel diarylurea derivatives (compounds of formula (I)) and their uses. The compounds of the present invention are demonstrated to be allosteric modulators of the CB1 receptor, and therefore useful for the treatment of diseases and conditions mediated by CB1.

Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents

In present study, 4-anilinoquinazolines scaffold, arylurea and tertiary amine moiety were combined to design, synthesize gefitinib analogs and discover novel anticancer agents. A series of 4-anilinoquinazoline derivatives (1, 2, 3 and 4) bearing arylurea and tertiary amine moiety at its 6-position were synthesized. Their antiproliferative activities in vitro were evaluated via MTT assay against A431 cell and A549 cell. The SAR of the title compounds was discussed. The compounds 2d, 2i and 2j with potent antiproliferative activities were evaluated their inhibitory activity against EGFR-TK. Compound 2j displayed potent inhibitory activity against EGFR-TK. In addition, compound 2j, at 50 mg/kg, can completely inhibit cancer growth in established nude mouse A549 xenograft model in vivo. These results suggest that the 4-anilinoquinazoline derivatives bearing diarylurea and tertiary amino moiety at its 6-position can serve as anticancer agents and EGFR inhibitors.

QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS

Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS

Provided herein are sirtuin-modulating compounds of formula (II) The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

8-SUBSTITUTED QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS

Provided herein are 8-substituted quinolines and related analogues as sirtuin-modulating compounds of Structural Formula (I) and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors

Compounds of formula (I): wherein Ra, Rb, R, X1 and X2 are as defined in the disclosure, pharmaceutical compositions comprising said compounds, processes for making and methods of using the same are provided.

AMINE COMPOUNDS

The present invention provide a compound of the formula:wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 and R5 are the same or different and each represents a hydrogen, etc.; R6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.